SRR35579838
— · D
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- D
- subtype
- D
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.450
- UV_RESPONSE_DN+0.400
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.360
- INTERFERON_GAMMA_RESPONSE+0.310
- MITOTIC_SPINDLE+0.240
- IL6_JAK_STAT3_SIGNALING+0.230
- HEDGEHOG_SIGNALING+0.190
- TGF_BETA_SIGNALING+0.170
- COMPLEMENT+0.160
- INFLAMMATORY_RESPONSE+0.080
Top 10 suppressed
- MYC_TARGETS_V1-0.590
- MYC_TARGETS_V2-0.480
- OXIDATIVE_PHOSPHORYLATION-0.460
- ESTROGEN_RESPONSE_LATE-0.440
- MTORC1_SIGNALING-0.400
- ESTROGEN_RESPONSE_EARLY-0.390
- UNFOLDED_PROTEIN_RESPONSE-0.370
- E2F_TARGETS-0.350
- UV_RESPONSE_UP-0.340
- CHOLESTEROL_HOMEOSTASIS-0.330
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR6013599 | — | cohortMD2 | 0.826 |
| 2 | TCGA-55-A57B-01A-12R-A39D-07 | — | cohortA1 | 0.824 |
| 3 | 30608f63-2604-489c-bf96-09e56acfe912 | — | — | 0.821 |
| 4 | SRR6013583 | — | cohortA1 | 0.820 |
| 5 | AUR-AG12-TTP1-A-1-0-R-A741-41 | — | A | 0.815 |
| 6 | TCGA-A7-A26F-01B-04R-A22O-07 | — | D | 0.813 |
| 7 | TCGA-93-A4JN-01A-11R-A24X-07 | — | cohortA1 | 0.803 |
| 8 | SRR15030864 | — | — | 0.798 |
| 9 | C3L-02957 | — | cohortMD2 | 0.793 |
| 10 | TCGA-A7-A26I-01B-06R-A22O-07 | — | D | 0.793 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.450 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.400 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.360 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.310 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.240 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.230 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.190 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.170 | Inavolisib | — uncovered |
| COMPLEMENT | 0.160 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.080 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.070 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.060 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.060 | Inavolisib | — uncovered |
| APOPTOSIS | 0.050 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.050 | Inavolisib | — uncovered |
| MYOGENESIS | 0.030 | Inavolisib | — uncovered |
| HYPOXIA | 0.010 | Idelalisib | — uncovered |